Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer.

[1]  W. Olszewski,et al.  PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors. , 2011, Human pathology.

[2]  Yoshikazu Ohta,et al.  Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein , 2011, The Journal of Biological Chemistry.

[3]  D. Sgroi,et al.  A Unique Spectrum of Somatic PIK3CA (p110α) Mutations Within Primary Endometrial Carcinomas , 2011, Clinical Cancer Research.

[4]  Toshimasa Tanaka,et al.  STRUCTURAL ANALYSIS OF THE MECHANISM OF INHIBITION AND ALLOSTERIC ACTIVATION OF THE KINASE DOMAIN OF HER 2 , 2011 .

[5]  C. Spearman.  The proof and measurement of association between two things. , 2015, International journal of epidemiology.

[6]  D. Friedecký,et al.  Lapatinib in breast cancer - the predictive significance of HER1 (EGFR), HER2, PTEN and PIK3CA genes and lapatinib plasma level assessment. , 2010, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.

[7]  W. M. Smit,et al.  Lapatinib: clinical benefit in patients with HER 2-positive advanced breast cancer. , 2010, The Netherlands journal of medicine.

[8]  K. Leslie,et al.  EGFR isoforms and gene regulation in human endometrial cancer cells , 2010, Molecular Cancer.

[9]  A. Goldhirsch,et al.  Lessons on responsiveness to adjuvant systemic therapies learned from the neoadjuvant setting. , 2009, Breast.

[10]  A. Mariani,et al.  HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer , 2008, British Journal of Cancer.

[11]  G. Yang,et al.  Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells , 2008, British Journal of Cancer.

[12]  J. Prat,et al.  PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters , 2008, Modern Pathology.

[13]  M. Casey,et al.  A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses , 2008, Breast Cancer Research and Treatment.

[14]  Meenakshi Singh,et al.  Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study. , 2007, Gynecologic oncology.

[15]  L. Mariani,et al.  Prognostic value of HER2 and progesterone receptor expression in endometrial carcinoma with positive peritoneal washing. , 2007, Anticancer Research.

[16]  M. Berger,et al.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.

[17]  K. Leslie,et al.  Regulation of signaling phosphoproteins by epidermal growth factor and Iressa (ZD1839) in human endometrial cancer cells that model type I and II tumors , 2005, Molecular Cancer Therapeutics.

[18]  M. Ostland,et al.  Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. Godwin,et al.  Phase II Study of Gefitinib in Patients with Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma and Evaluation of Epidermal Growth Factor Receptor Mutations and Immunohistochemical Expression: A Gynecologic Oncology Group Study , 2005, Clinical Cancer Research.

[20]  E. Siegel,et al.  Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer. , 2005, American journal of obstetrics and gynecology.

[21]  K. Leslie,et al.  TYROSINE KINASE INHIBITORS IN ENDOMETRIAL CANCER: 0020 , 2005, International Journal of Gynecologic Cancer.

[22]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[23]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[24]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[25]  L. Kuyper,et al.  Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase. , 2000, Journal of medicinal chemistry.

[26]  A. Ebert,et al.  Expression and Function of Egf-Related Peptides and Their Receptors in Gynecological Cancer - From Basic Science to Therapy? , 2000, Journal of receptor and signal transduction research.

[27]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[28]  Nitin R. Patel,et al.  A Network Algorithm for Performing Fisher's Exact Test in r × c Contingency Tables , 1983 .

[29]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[30]  M. Kendall.  The treatment of ties in ranking problems. , 1945, Biometrika.

[31]  M. Kendall.  Statistical Methods for Research Workers , 1937, Nature.

[32]  D.,et al.  Regression Models and Life-Tables , 2022 .